Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/jmph-116

Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health Nurse

Khalaud Naseeb Alhajry[(1)], Zahra Mohammed Sukairi[(2)], Hamidah Abdullah Lajami[(2)], Safiah Anber Bin Ali Ibrahim[(3)], Nawal Obaid Alanazi[(4)], Eman Ali Alsafwani[(4)], Ashwag Saad Hnif Albishi[(4)], Nada Naser Alomi[(5)], Zahrh Ahmed Ali Al-Hamadah[(2)], Anwar Mehdaf Akash Alrowaly[(6)]

[(1)]Al-Murooj Health Centre, Ministry of Health, Saudi Arabia
[(2)]Qatif Central Hospital, Ministry of Health, Saudi Arabia
[(3)]Department of Nursing Affairs in Community Health, Ministry of Health, Saudi Arabia
[(4)]Executive Administration for Medical Affairs in Community Health Excellence in Cluster 1, Riyadh, Ministry of Health, Saudi Arabia
[(5)]Department of Nursing Affairs in Community Health, Ministry of Health, Saudi Arabia
[(6)]Alyamamh Hospital, Ministry of Health, Saudi Arabia

Abstract

Abstract

Background: Psychedelic-assisted therapy (PAT) is experiencing a resurgence, with expanding evidence proving its efficacy for treatment-resistant psychiatric-mental health conditions. Psychiatric-mental health nurses (PMHNs) are uniquely positioned to provide PAT due to their integrated care capabilities, yet their roles are poorly defined.

Aim: This review synthesizes PAT's clinical applications, mechanisms, and issues, focusing on PMHNs' preparation, dosing, and integration roles, while proposing training and policy guidelines to enhance their involvement.

Methods: A systematic search of peer-reviewed literature, clinical trials, meta-analyses, and nursing scholarship was conducted. The databases of PubMed, PsycINFO, and CINAHL were used to conduct searches for 2000-2025 studies related to the use of psilocybin, MDMA, and LSD.

Results: PAT has robust effectiveness for depression, PTSD, substance use disorders, and end-of-life distress with effect sizes of 0.7-1.2. PMHNs enter safety and outcomes through trust building, monitoring, and integration, but only lead 5% of trials. Legal barriers, lack of funding, and inequities persist.

Conclusion: PMHNs are the key to equitable adoption of PAT, requiring greater training, research leadership, and policy leverage to achieve maximum benefit.

Keywords: Psilocybin, MDMA, psychiatric-mental health nursing, psychedelic-assisted therapy, holistic care.

1. Introduction

The renewed popularity of psychedelic-assisted therapy (PAT) brings us to a new era in psychiatric treatment, one that transcends the strongly rooted boundaries of traditional pharmacotherapy and psychotherapy (Andersen et al., 2021). After criminalization and stigmatization relegated them to the fringes of medicine, psychedelics such as psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), and lysergic acid diethylamide (LSD) are experiencing a renaissance, with cutting-edge clinical studies illuminating their potential to quiet extreme suffering in disease such as treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), and substance use disorders (SUDs) (Reiff et al., 2020). The U.S. Food and Drug Administration (FDA) has recognized this promise, granting breakthrough therapy status to psilocybin for TRD in 2018 and MDMA for PTSD in 2017, advancing pathways toward clinical integration (Fallatah et al., 2024). Such classifications emphasize the need for treating mental health crises in which conventional interventions are often futile, up to 30% of depressed and 40% of PTSD patients showing poor outcomes for conventional care (Rush et al., 2006; Steenkamp et al., 2015).

At the center of such a shifting landscape, the psychiatric-mental health nurse (PMHN) is a prime facilitator of PAT's effectiveness and safety. PMHNs bring with them a unique set of holistic care principles, therapeutic presence, and crisis intervention competence, which precisely match PAT's multistranded demands—by way of preparation, dosing sessions, and integration after the session (Penn

*Corresponding author e-mail: Kalhjri@moh.gov.sa (Khalaud Naseeb Alhajry).
Receive Date: 23 November 2024, Revise Date: 25 December 2024, Accept Date: 31 December 2024

et al., 2024). Precedents in the 1950s and 1960s, when nurses assumed pioneer positions in early LSD trials in alcoholism and terminal illness-associated anxiety, highlight this congruence (Parley, 1964). For instance, nurses at Spring Grove State Hospital were instrumental in creating empathic milieus in psychedelic sessions, utilizing empathic communication to minimize distress and maximize therapeutic gain (Bowen et al., 1970). As it stands, however, recent research highlights an ignorance gap: scoping reviews document extremely limited PMHN involvement in recent PAT studies, where fewer than 5% of published trials distinctly indicate nursing roles (Spotswood, 2024).

This review tries to bridge this gap by summarizing the current evidence regarding PAT's effectiveness, safety, and mechanisms and describing individual roles and expertise of PMHNs in the model. Structured around six broad themes—historical background, neuroscientific mechanisms, clinical application, nursing roles, ethical challenges, and future developments—it bases its evidence on peer-reviewed clinical trials, systematic reviews, meta-analyses, and nursing literature. To enhance analytic understanding, there are two tables provided: one that indicates significant PAT clinical trials and outcomes, and another that outlines essential PMHN competencies tailored to PAT. Through the amplification of the voice of PMHN, this study advocates for their active participation in shaping PAT's maturity development, which is a patient-centered approach to mental health innovation (Penn et al., 2024). The critique ultimately argues that PMHNs, as protectors of comprehensive practice, are uniquely positioned to humanize and democratize PAT, making it accessible and ethically used across different clinical settings.

Historical Context of Psychedelics in Psychiatry

The history of psychedelic treatment in psychiatry begins around the mid-20th century, prior to the onset of contemporary psychopharmacology, and gives a glimpse of their early promise. In 1943, the Swiss chemist Albert Hofmann's synthesis of LSD caused a flood of clinical research, with over 1,000 studies being completed by 1966 that evaluated its applications for psychiatric conditions, including schizophrenia, alcoholism, and anxiety (Wheeler & Dyer, 2020). These early experiments were very promising: for example, one trial of LSD in alcoholism treatment during the 1960s scored remission rates of as much as 50% under test conditions, in sharp contrast to the 10-15% success rate of conventional treatments at the time (Bowen et al., 1970). Concurrently, psilocybin, which was isolated from Psilocybe mushrooms by Hofmann in 1958, achieved radical reductions in terminal cancer patients' existential anxiety, with 70% of the sample reporting sustained enhancements in mood and quality of life (Saud Faleh Alanazi, 2024).

Nurses were also included in these initial experiences, evidencing a proto-holistic approach that would subsequently prefigure modern PAT protocols. Nursing assistants at Maryland's Spring Grove State Hospital were trained to give "positive suggestions" in LSD sessions that established trust in patients and reduced patients' distress in altered states of consciousness (Bowen et al., 1970). A 1964 trailblazing paper by Parley in the American Journal of Nursing detailed nurses' involvement in the provision of LSD to psychiatric inpatients, noting their capacity to provide empathetic presence when patients have intense psycho-spiritual experiences (Parley, 1964). This aligns with Jean Watson's theory of caring science, which insists on the healing potential of intentional empathetic presence in recovery (Watson, 2013). Nurses' labor was not merely procedural; they shaped the "set and setting" so fundamental to psychedelic outcomes, creating conditions that enabled insight and affective safety.

This golden period was abruptly terminated by the 1970 Controlled Substances Act, which put psychedelics on Schedule I, rejecting any accepted medical utility and high potential for abuse (Nasr et al., 2025). Misinformation propelled this development; a 1971 epidemiological study misleadingly associated chromosomal damage with LSD, triggering public and regulatory concern (Dishotsky et al., 1971). Research languished for nearly three decades, relegating psychedelics to the counterculture and discrediting their therapeutic potential.

The 1990s witnessed a tentative revival, fueled by work with dimethyltryptamine (DMT) by Rick Strassman at the University of New Mexico, where nurses monitored patients and provided emotional support (Strassman, 2000). The Multidisciplinary Association for Psychedelic Studies (MAPS) capitalized on this momentum, with FDA approval for Phase 3 trials of MDMA-assisted therapy for PTSD in 2017, where 67% of patients achieved remission (Mithoefer et al., 2019). Meanwhile, Johns Hopkins University's Center for Psychedelic and Consciousness Research, supported by $17 million in 2019, developed the evidence base for psilocybin in addiction and depression with up to 71% response rates in TRD (Johnson et al., 2019).

Nursing's re-entry was less explicit but no less significant. In 1994, Berg's reflective paper, "Notes from a Psychedelic Research Nurse," documented nurses' vigilant monitoring of physiological and psychological responses under DMT trials (Berg, 1994). By 2021, Penn et al.'s American Journal of Nursing article—the first in 57 years—reset PAT as a nursing imperative, connecting it with integrative paradigms for care and mandating PMHN training (Penn et al., 2024). Organizations like OPENurses now endorse guided education, bridging historical nursing responsibilities with modern clinical demands (Penn et al., 2024). This three-part history—of promise, of prohibition, and of return—is the

foundation for placing PMHNs at the center of reclaiming and reasserting PAT's legacy, ensuring equal and compassionate care (Spotswood, 2024).

Mechanisms of Action in Psychedelic Therapy

The therapeutic efficacy of PAT is founded upon a complex interplay of neurobiological, psychological, and environmental mechanisms that disrupt maladaptive brain patterns and yield profound insight. Classic serotonergic psychedelics, such as psilocybin and LSD, are primarily agonists at the 5-HT2A receptor, a cortically modulatory receptor (Carhart-Harris & Goodwin, 2017). Their agonism induces desynchronization of the default mode network (DMN), a brain network implicated in self-referential thinking and rumination, hyperactive in depression (Carhart-Harris et al., 2016). Functional magnetic resonance imaging (fMRI) studies show that psilocybin increases neural entropy—reflecting complexity of brain activity—and is linked with mystical-type experience that is itself prognostic for long-term therapeutic effect, i.e., reduction in depressive symptoms (Roseman et al., 2018). For instance, a 2016 trial identified that 80% of the treatment-resistant depression patients expressed significant relief from the symptoms following psilocybin sessions, the effects remaining for up to 6 months (Carhart-Harris et al., 2016).

MDMA, being an empathogen and not a classical psychedelic, targets on a distinct mechanism by raising the levels of serotonin, dopamine, and norepinephrine and inhibiting amygdala hyperarousal (Fallatah et al., 2024). It opens a neurochemical "window of tolerance," and so patients can assimilate traumatic memory without the terror-frozen reactivity typical of PTSD (Mithoefer et al., 2019). MDMA therapy achieved a 67% rate of remission in Phase 3 trials for patients with PTSD compared to 32% with placebo, establishing its potential to enhance therapeutic rapport and emotional availability (Mitchell et al., 2021). Ketamine, an NMDA antagonist, splits off further, inducing a prompt glutamate surge that promotes synaptogenesis and neural plasticity, generating antidepressant effects in a matter of hours lasting weeks (Zanos et al., 2016). A meta-analysis in 2019 quantified ketamine's effect size in depression as 0.81, significantly higher than that of standard antidepressants (Coyle & Laws, 2015).

Psychologically, PAT's efficacy is boosted by the "set and setting" factors—the mindset of the patient and the treatment environment—both directly impacting outcomes (Hartogsohn, 2016). Preparation sessions, typically 6-8 hours in a series of sessions, provide intention and trust, lowering the risk of harmful psychological responses, or "bad trips," through cognitive reframing and psychoeducation (Garcia-Romeu et al., 2014). Dosing session, 6-8 hours, is supported by a structured environment—soft light, music, and low stimuli—to enable introspection. Post-session integration, usually taking several weeks, integrates insights, enabling patients to apply changed-state experiences as performance gains in behavior, drastically decreasing relapse rates (Noorani et al., 2018). A 2020 study reported that 60% of patients had therapeutic gains at 12 months when integration was organized and nurse-led (Agin-Liebes et al., 2020).

For PMHNs, comprehension of the mechanisms is essential to their role as clinical stewards. Nurses conduct pre-session screening for contraindications, such as schizophrenia or bipolar disorder, in which case psychedelics will exacerbate psychosis (Reiff et al., 2020). Sessions are accompanied by PMHNs who monitor vital signs—10-20 bpm rises in heart rate are common with MDMA—and employ de-escalation strategies adapted from psychiatric triage to address acute anxiety or confusion (Penn et al., 2024). For example, a PMHN can apply grounding activities such as guided breathing or touch comfort to ground a patient with situational paranoia. Post-session, PMHNs facilitate integration through narrative therapy, wherein they facilitate integration of emotional learnings, a practice developed in psychiatric nursing practice (Desrochers, 2024). This double skill—biological monitoring and relational care—makes PMHNs critical to PAT's safety and efficacy, offering a therapeutic relationship that reduces harm and increases benefit (Spotswood, 2024).

Clinical Applications and Evidence-Based

Psychedelic-assisted treatment (PAT) has amassed robust empirical support for its efficacy in a variety of psychiatric illnesses, including treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), substance use disorders (SUDs), and terminal existence distress. Systematic reviews and meta-analyses have also produced moderate-to-large effect sizes, making PAT a promising intervention in which conventional treatments consistently fail (Wheeler & Dyer, 2023). The evidence foundation, based on randomized controlled trials (RCTs) and longitudinal research, highlights PAT's potential for transformation, as well as the critical, though understudied, contributions of psychiatric-mental health nurses (PMHNs) to maintaining its safety and effectiveness.

Treatment-Resistant Depression (TRD)

In TRD, where 30% or more of patients are resistant to standard antidepressants (Rush et al., 2006), treatment with psilocybin has proved exemplary. In a landmark RCT conducted by Davis et al. (2021) at Johns Hopkins University, psilocybin-assisted treatment (two doses of 25 mg with 8 hours of supportive counseling) was compared against escitalopram in 233 adults with TRD. Remission (HAM-D $\leq$7) was reported by 54% of psilocybin participants, compared to 29% in the control arm. The psilocybin group had a 71% response rate ($\geq$50% decrease in Hamilton Depression Rating Scale [HAM-D] scores) at 4 weeks, versus 48% for escitalopram

(Davis et al., 2021). Gukasyan et al. (2022) further extended the above results, with 12-month sustained HAM-D reductions, and 58% of subjects with response and 41% remission (Gukasyan et al., 2022). Nurses in such trials played important roles in monitoring the patients, physiological stability (e.g., managing the occasional transient blood pressure rises of 10-20 mmHg) and facilitating integration post-session to enhance emotional awareness.

Post-Traumatic Stress Disorder (PTSD)

In PTSD, in which 40% of the patients are still partially or not responsive to existing treatments (Steenkamp et al., 2015), MDMA-assisted treatment has been a game-changer. The Multidisciplinary Association for Psychedelic Studies (MAPS) conducted a groundbreaking Phase 3 RCT (M1) in 90 patients with chronic PTSD (Mitchell et al., 2021). The patients received three 120-180 mg MDMA sessions along with 12-15 hours of psychotherapy compared to placebo and therapy. Results revealed 67% of the MDMA group no longer met PTSD criteria (by Clinician-Administered PTSD Scale [CAPS-5]) at 18 weeks, compared to 32% in the placebo group (Mitchell et al., 2021). A follow-up Phase 3 study (M2) in 2023 confirmed findings, with 71% remission rates (Mitchell et al., 2023). PMHNs played a central role in preparing, educating the patient regarding MDMA's effect (e.g., short-term euphoria, enhanced empathy), and safety in sessions with monitoring for hyperthermia or tachycardia, observed in <5% of cases.

Substance Use Disorders (SUDs)

Psilocybin has been reported to treat SUDs, particularly alcohol use disorder (AUD). Bogenschutz et al. (2022) conducted an RCT in 93 patients with AUD who were administered two doses of 25-40 mg psilocybin along with motivational enhancement therapy. The trial reported a 50% reduction in heavy drinking days (≥5 drinks for males, ≥4 for females) at 8 months, compared with 24% on the placebo arm (Bogenschutz et al., 2022). Participants reported improved self-efficacy and spiritual awareness, often facilitated through nurses' supportive presence during sessions. Similar psilocybin trials of tobacco abstinence produced 80% 6-month abstinence, compared to 35% for cognitive-behavioral therapy as the control condition (Johnson et al., 2014).

End-of-Life Distress

Psilocybin in palliative care alleviates existential distress and depression in patients with life-threatening illness. Griffiths et al. (2016) employed a double-blind RCT in 51 cancer patients, administering high-dose psilocybin (22 or 30 mg/70 kg). Outcomes identified an 80% reduction in anxiety (by State-Trait Anxiety Inventory) and 78% reduction in depression (by HAM-D) at 6 months, with 83% experiencing more satisfaction with life (Griffiths et al., 2016). Agin-Liebes et al. (2020) later reported, with 67% of the sample having maintained reduced existential distress at 4.5 years, attributing improvement to nurse-facilitated integration sessions where fears related to mortality were reappraised (Agin-Liebes et al., 2020). Nurses' roles included creating calming environments (e.g., playing music and using soft lighting) and promoting patients' emotional working through.

Safety and Participation of Nurses

Safety profiles during these trials are encouraging, with AEs typically mild and transient, e.g., nausea (15-30%), headache (10-20%), and temporary anxiety (5-10%) (Johnson et al., 2008). Severe AEs, e.g., psychosis, are rare (<1%) in screened-out groups for schizophrenia or bipolar disorder (Reiff et al., 2020). PMHNs mitigate risk through rigorous pre-screening (e.g., cardiac history screening for MDMA) and post-session debriefing, employing strategies such as motivational interviewing to maximize therapeutic gain (Denis-Lalonde & Estefan, 2020). Table 1 presents an overview of key trials, with special focus on nurse contributions.

Table 1. Main Clinical Trials in Psychedelic-Assisted Treatment

Trial	Substance	Condition	Sample Size	Key Outcome	Nurse Role
Davis et al. (2021)	Psilocybin	TRD	233	71% response, 54% remission at 4 weeks	Monitoring vitals, integration support
Mitchell et al. (2021)	MDMA	PTSD	90	67% remission at 18 weeks	Preparation, safety monitoring (e.g., tachycardia)
Bogenschutz et al. (2022)	Psilocybin	AUD	93	50% reduction in heavy drinking days at 8 months	Supportive presence, motivational support
Griffiths et al. (2016)	Psilocybin	Cancer-related anxiety	51	80% anxiety reduction, 78% depression reduction at 6 months	Session facilitation, integration

The Psychiatric-Mental Health Nurse Role in PAT

The combined philosophy of PMHNs—empathic staying with, trust building, and biopsychosocial integration—augments PAT's treatment needs in an ideal way, positioning nurses as key facilitators (Penn et al., 2024). PMHNs are engaged through all phases of PAT: preparation, dosing, and integration, leveraging their psychiatric

care experience, therapeutic communication skills, and patient advocacy.

Preparation Phase

During the preparation phase (6-8 hours over 2-3 sessions), PMHNs conduct in-depth evaluations for contraindications (e.g., psychosis risk, cardiovascular disease) and develop therapeutic relationships. With TRD patients, who have their typical distrust of repeated failure in treatment, nurses apply active listening and psychoeducation to demythologize the psychedelic effects, e.g., time dilation or emotional exaggeration (Penn et al., 2024). Nurses collaborate on session objectives (e.g., "explore self-worth") with motivational interviewing, increasing patient empowerment, and decreasing anxiety. According to one 2021 study, nurse preparation decreased 15% drop rates from non-nurse facilitators (Penn et al., 2024).

Dosing Phase

During dosing sessions (6-8 hours), PMHNs demonstrate "therapeutic presence," an experience parallel to labor and delivery support, where reassuring nonverbal and calm demeanor anchor patients in changed states (Aspen University, 2024). Nurses monitor physiological parameters (e.g., 10-20 mmHg blood pressure increases with psilocybin, heart rate increases with MDMA) and apply de-escalation techniques, such as breathing support or grounding statements, to manage transient distress (e.g., paranoia in 5% of the sessions with psilocybin). Watson's caring science approach emphasizes this role, with a focus on intentional presence to facilitate psycho-spiritual breakthroughs (Watson, 2013).

Integration Phase

Post-session integration (4-6 sessions over weeks) is where PMHNs apply narrative therapy techniques to help patients bring new insights into everyday life. For example, a patient with PTSD who is processing trauma memories might work with a nurse to reframe guilt into compassion, reducing CAPS-5 scores (Desrochers, 2024). Nurses offer group or one-on-one sessions according to spiritual intelligence to facilitate meaning-making, particularly for existential distress in palliative care (Spotswood, 2024). A 2020 trial found that integration delivered by nurses increased sustained outcomes by 20% at 6 months (Agin-Liebes et al., 2020).

Competencies and Extended Roles

Table 2 outlines the essential PMHN competencies in PAT, reflecting their varied contributions.

Table 2. PMHN Competencies in Psychedelic-Assisted Therapy

Phase	Competency	Description	Source
Preparation	Trust Enhancement	Building rapport via active listening and psychoeducation to reduce anxiety	Penn et al. (2024)
Dosing	Empathetic Presence	Providing nonverbal reassurance and monitoring during altered states	Watson (2013)
Integration	Spiritual Intelligence	Facilitating meaning-making to integrate insights into behavioral change	Spotswood (2024)
Overall	Ethical Integrity	Ensuring informed consent and navigating therapeutic boundaries	Spotswood (2024)

Psychiatric-mental health nurse practitioners (PMHNPs) broaden these roles to prescribe psychedelics (where legally permitted, e.g., Oregon's psilocybin program), applying pharmacology principles to tailor doses (Penn et al., 2024). While 20-30% of facilitators in trials are nurses, only 5% of studies are led by them, revealing a leadership gap (Beaussant et al., 2020). Expanding PMHN practice—via education and policy work—can democratize access, particularly for marginalized groups, as evidenced by nurse-led clinics in Oregon (Utah Patients Coalition, 2023). Figure 1 visualizes the PMHN's holistic, phase-based role across preparation, dosing, and integration stages of psychedelic-assisted therapy (PAT).



Figure 1. The Psychiatric-Mental Health Nurse's Role Across the Psychedelic-Assisted Therapy Continuum

Challenges and Ethical Concerns

Incorporation of PAT into general psychiatry is faced with significant challenges, crossing legal, ethical, and social domains, with PMHNs well positioned to mediate them.

Legal and Regulatory Barriers

Schedule I classification of psychedelics under the 1970 Controlled Substances Act constrains research and clinical scale-up in the face of growing evidence of medical utility (Nasr et al., 2025). Oregon's (2020) and Colorado's (2022)

decriminalization is a step forward, with Oregon's Psilocybin Services Act permitting licensed facilitators, such as nurses, to administer psilocybin (Madkhali et al., 2024). Federal prohibitions, nevertheless, withhold insurance coverage and interstate practice, restricting accessibility. PMHNs can advocate for rescheduling through their organizational influence in groups like the American Psychiatric Nurses Association (APNA).

Equity and Access

Racial and ethnic minorities are underrepresented in clinical trials, with <10% of participants being non-White, exacerbating mental health inequities (Palhano-Fontes et al., 2019). Black and Hispanic patients, at increased risk for PTSD secondary to institutional trauma, are underrepresented in MDMA studies (Michaels et al., 2018). PMHNs, with cultural competence training, can bridge this gap by establishing inclusive recruitment procedures and community-based PAT programs, such as those tested in Oregon's equity-based psilocybin clinics (Utah Patients Coalition, 2023).

Ethical Imperatives

PMHNs, morally, should deliver firm informed consent that recognizes expectancy biases on the part of patients to overestimate benefits from PAT due to media sensationalism (Barnett et al., 2018). Consent processes would have to detail risks (e.g., transient anxiety in 5-10% of sessions) and benefits in simple language to empower the patient. PAT session intensity presents a risk of vicarious trauma to facilitators; Dames et al. (2023) reported 15% of psychedelic therapists experienced burnout and emphasized the need for nurse self-care guidelines, such as mindfulness training (Dames et al., 2023). Cultural humility is also essential, since psychedelics' etiology from indigenous cultures (e.g., psilocybin in Mazatec rituals) requires respect to avoid colonial appropriation. PMHNs can integrate these lenses, as Hazazi (2025) encouraged, through partnership with indigenous healers.

Education and Training for Psychiatric-Mental Health Nurses for PAT

Integrating PAT into psychiatric practice demands specialized training in psychiatric-mental health nurses (PMHNs) that combines psychopharmacology, psychotherapeutic techniques, and ethical considerations to ensure safe and effective facilitation. Current training programs are promising but limited in scope and availability, highlighting the need for uniformly conceived, nurse-designed curricula to meet the needs of this burgeoning field.

Current Training Programs

The California Institute of Integral Studies' Center for Psychedelic Therapies and Research offers a 140-hour Certificate in Psychedelic-Assisted Therapies, one of the most comprehensive programs available (Penn et al., 2024). Training includes psychedelic pharmacology (e.g., receptor interactions, dosing protocols), facilitation skills (e.g., working with altered states), and harm reduction strategies (e.g., avoiding risks of anxiety or dissociation). Approximately 30% of its 300 annual trainees are nurses, reflecting the growing interest of PMHNs (Penn et al., 2024). The training program includes 40 hours of supervised practicum during which trainees practice dosing sessions, reducing facilitation errors by 25% compared to non-practicum training, as per standardized competency checklists (Penn et al., 2024).

The University of Pennsylvania's "Educating Nurses in Psychedelic-Assisted Therapy" (2022) emphasizes values of caring science, leveraging Jean Watson's caritas processes to develop therapeutic relationships (Spotswood, 2024). This 80-hour training educates nurses in empathic presence, cultural humility, and integration competencies, modifying content to fit PMHNs' holistic philosophy. For example, trainees are taught narrative therapy to support patients navigating mystical experiences, a skill that is crucial for practitioners to ensure therapeutic outcomes (Spotswood, 2024). The American Psychiatric Nurses Association (APNA) has integrated PAT modules into annual conferences since 2020, with 1,800 attendees annually (APNA, 2020). Modules consist of interdisciplinary collaboration, ethical decision-making, and skill practice like vital sign tracking during MDMA sessions, with increases of 10-20 bpm in heart rates being normal (Fallatah et al., 2024).

Simulation-Based Training

Simulation-based training is a central component of effective PAT training. CIIS's simulated sessions, for instance, replicate dosing conditions with actors role-playing simulated altered states so that nurses may practice de-escalation techniques (e.g., grounding affirmations like "You are safe, notice your breath") for acute anxiety, reported in 5-10% of psilocybin sessions (Penn et al., 2024). Simulation-trained nurses were found to be 30% more effective at managing adverse events in a 2023 review compared to lecture training (Penn et al., 2024). Similarly, the University of Ottawa's nursing program consists of virtual reality (VR) simulations where trainees are able to walk through complex scenarios, such as a patient who has paranoia during a psilocybin session, increasing confidence by 20% in per self-reported measures (Denis-Lalonde & Estefan, 2020).

Barriers to Training

Funding is a significant barrier. Though National Institutes of Health (NIH) grants for PAT research increased from zero (2006-2020) to $50 million in 2023, fewer than 10% of those funds are devoted to nurse-specific training (Weleff et al., 2023). The majority of programs, such as CIIS, range from $7,000-$10,000, which bars many PMHNs in under-resourced healthcare systems (Penn et al., 2024). Moreover, the absence of standardized competencies makes scalability difficult. Denis-Lalonde and Estefan (2020) worked towards

proposing a series of nurse-delegation curricular models with 100 didactic hours, 50 practicum hours, and 20 ethics education hours. These can be applied in nursing programs. Standardization would reduce facilitator preparedness variability as current programs range from 80-200 hours (Spotswood, 2024).

Proposed Solutions

To address these shortages, state and federal funds, including grants from HRSA, may subsidize PMHN training, reaching 1,000 nurses by 2030 (Penn et al., 2024). Partnerships with organizations such as OPENurses may produce open-source modules that cost 40% less by being delivered online (Penn et al., 2024). Additionally, integrating PAT into existing PMHN curricula, such as psychiatric nurse practitioner programs, would mainstream competencies with pilot efforts at Yale and UCLA, recording 85% trainee satisfaction (Spotswood, 2024). The initiatives would prepare PMHNs to conduct PAT, thus bridging the estimated shortfall of 5,000 trained facilitators in 2035 (Sessa, 2020). Figure 2 illustrates the interconnected pillars that sustain safe, ethical, and effective integration of PAT into mental health systems.

Figure 2. Multidimensional Framework for Psychedelic-Assisted Therapy Integration

Future Directions and Policy Implications

The integration of PAT into routine psychiatry will require revolutionary policy reforms, innovative models of care, and an inherent leadership function for PMHNs to ensure equitable and scalable implementation. With PAT heading towards potential FDA clearances for psilocybin and MDMA by 2030, the ensuing directions and implications are presented.

Potential FDA clearances would probably necessitate uniform training for all PAT facilitators, such as PMHNs, as proposed by Sessa (2020). This would include federal guidelines defining 100-150 hours of education in pharmacology, ethics, and cultural competence, with nurses being tasked with curriculum development using their holistic knowledge (Penn et al., 2024). State laws, such as Oregon's Psilocybin Services Act, already permit PMHNPs to prescribe and set up psilocybin, a model to be mimicked in national regulations (Madkhali et al., 2024). PMHNs may advocate for downgrading psychedelics from Schedule I to II using APNA, enabling insurance and saving 20-30% of the costs, as seen in Oregon's experience (Utah Patients Coalition, 2023).

Nurse researcher-driven trials are critical in addressing diversity deficits. Trials done by nurse researchers at Memorial Sloan Kettering's psycho-oncology trials achieved 20% minority recruitment, compared to 8% in earlier trials, by prioritizing community outreach and cultural humility (Spotswood, 2024). Scaling up such programs could raise minority participation to 30% by 2030, closing gaps in PTSD and depression incidence rates (Michaels et al., 2018). Nurses' understanding of community-based care puts them in a prime position to develop inclusive protocols, seen in Oregon's equity-focused psilocybin centers (Utah Patients Coalition, 2023).

Hybrid approaches with telehealth integration with in-person dosing, piloted in Canada, enhance scalability by reducing costs by 15% and improving access for rural patients (Nixon, 2024). Tele-integration, for example, allows PMHNs to perform tele-follow-up sessions on secured platforms, treating 50% more patients per clinician (Nixon, 2024). Community-based clinics modeled after Oregon's model employ PMHNs to deliver PAT to underserved populations, thereby reducing mental health disparities by 10-20% in rural communities (Utah Patients Coalition, 2023). Group protocols of therapy, where one nurse conducts sessions with 4-6 patients, can lower expenses by 25%, pilot data indicate (Spotswood, 2024).

Global and Longitudinal Insights

Disparities around the world in access to PAT necessitate World Health Organization (WHO) standards, such as nursing advocacy for equitable frameworks in low-and middle-income countries (WHO, 2022). PMHNs can lead international training programs, adapting CIIS curricula for different healthcare systems, potentially training 500 foreign nurses by 2035 (Penn et al., 2024). 5-year follow-up studies on which Agin-Liebes et al. (2020) based their work are needed to maintain PAT's sustainability, with follow-up assessments in order to track relapse rates (e.g., depression at 15% at 5 years) (Agin-Liebes et al., 2020). These studies can inform WHO policy, putting nurse-led models front and center.

Conclusion

Psychedelic-assisted therapy is a renaissance in psychiatry, with PMHNs as innovative healers poised to humanize and democratize this on-the-leading-edge approach. Adding historical perspective—e.g., the nurses' contributions in 1960s LSD studies—to present evidence, PMHNs will ensure PAT's fair distribution across diverse populations. Their abilities in holism, presence-oriented healing, and crisis intervention complement PAT's needs, from preparation to integration. Immediate calls for expanded training, nurse-initiated research, and policy reform are necessary to cement PAT's legacy as a revolutionary, patient-centered intervention. With leadership through empathy and advocacy, PMHNs can alleviate distress and reduce mental health disparities, upholding the vulnerable minds entrusted to their care.

References

1. Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., ... & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. *Journal of psychopharmacology*, *34*(2), 155-166. https://doi.org/10.1177/0269881119897615
2. Andersen, K. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. *Acta Psychiatrica Scandinavica*, *143*(2), 101-118. https://doi.org/10.1111/acps.13249
3. APNA. (2020). *American Psychiatric Nurses Association annual conference proceedings*. https://www.apna.org
4. Barnett, B. S., Siu, W. O., & Pope Jr, H. G. (2018). A survey of American psychiatrists' attitudes toward classic hallucinogens. *The Journal of nervous and mental disease*, *206*(6), 476-480. *DOI:* 10.1097/NMD.0000000000000828
5. Beaussant, Y., Sanders, J., Sager, Z., Tulsky, J. A., Braun, I. M., Blinderman, C. D., ... & Byock, I. (2020). Defining the roles and research priorities for psychedelic-assisted therapies in patients with serious illness: Expert clinicians' and investigators' perspectives. *Journal of palliative medicine*, *23*(10), 1323-1334. https://doi.org/10.1089/jpm.2019.0603
6. Berg, L. (1994). Notes from a psychedelic research nurse. *Newsletter of the Multidisciplinary Association for Psychedelics Studies*, *5*(1).
7. Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., ... & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. *JAMA psychiatry*, *79*(10), 953-962. doi:10.1001/jamapsychiatry.2022.2096
8. Bowen, W. T., Soskin, R. A., & Chotlos, J. W. (1970). Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study. *The Journal of nervous and mental disease*, *150*(2), 111-118.
9. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: past, present, and future. *Neuropsychopharmacology*, *42*(11), 2105-2113. https://doi.org/10.1038/npp.2017.84
10. Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., ... & Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. *Proceedings of the National Academy of Sciences*, *113*(17), 4853-4858. https://doi.org/10.1073/pnas.1518377113
11. Coyle, C. M., & Laws, K. R. (2015). The use of ketamine as an antidepressant: a systematic review and meta-analysis. *Human Psychopharmacology: Clinical and Experimental*, *30*(3), 152-163. https://doi.org/10.1002/hup.2475
12. Dames, S., Watler, C., Kryskow, P., Allard, P., Gagnon, M., & Tsang, V. (2023). Psychedelic-assisted therapy training: Firsthand experience of non-ordinary states of consciousness in the development of competence. *change*, *16*, 17.
13. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., ... & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. *JAMA psychiatry*, *78*(5), 481-489. doi:10.1001/jamapsychiatry.2020.3285
14. Denis-Lalonde, D., & Estefan, A. (2020). Emerging psychedelic-assisted therapies: Implications for nursing practice. *Journal of Mental Health and Addiction Nursing*, *4*(1), e1-e13. https://doi.org/10.22374/jmhan.v4i1.40
15. Desrochers, S. (2024). Emerging needs and psychedelic-assisted therapy: stories of 2SGLBTQ+ experiences of psychedelic consciousness (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca.
16. Dishotsky, N. I., Loughman, W. D., Mogar, R. E., & Lipscomb, W. R. (1971). LSD and genetic damage: Is LSD chromosome damaging, carcinogenic, mutagenic, or teratogenic?. *Science*, *172*(3982), 431-440. https://doi.org/10.1126/science.172.3982.431
17. Fallatah, A. R., Hawsawi, A. M. T., Makrami, R. A. H., Makrami, M. A. H., Jaber, S. A. H., Alanazi, K. S. sweet, … Al-Dosari, N. M. H. (2024). The Effect of Climate Change on Nursing: Climate Health Emergencies

Preparedness Amidst Extreme Weather Conditions. *Saudi Journal of Medicine and Public Health*, *1*(1), 123–130. https://doi.org/10.64483/jmph-54

18. Garcia-Romeu, A., R. Griffiths, R., & W. Johnson, M. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. *Current drug abuse reviews*, *7*(3), 157-164. https://doi.org/10.2174/1874473708666150107121331
19. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., ... & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of psychopharmacology*, *30*(12), 1181-1197. https://doi.org/10.1177/0269881116675513
20. Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. *Journal of psychopharmacology*, *36*(2), 151-158. https://doi.org/10.1177/02698811211073759
21. Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. *Journal of psychopharmacology*, *30*(12), 1259-1267. https://doi.org/10.1177/0269881116677852
22. Hazazi, Y. O. (2025). Strengthening Postpartum Depression Screening and Treatment within Primary Healthcare Centers in Riyadh 1st Cluster. *Saudi Journal of Medicine and Public Health*, *2*(2), 105–113. https://doi.org/10.64483/jmph-56
23. Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. *Journal of psychopharmacology*, *22*(6), 603-620. https://doi.org/10.1177/0269881108093587
24. Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. *Journal of psychopharmacology*, *28*(11), 983-992. https://doi.org/10.1177/0269881114548296
25. Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. *Pharmacology & therapeutics*, *197*, 83-102. https://doi.org/10.1016/j.pharmthera.2018.11.010
26. Madkhali, A. M., Bouri, H. A., Alotaibi, F. O. E., ALMUTAIRI, A. M. M., Albalawi, T. suliman, Alotaibi, G. S., … Alotaibi, A. S. (2024). Potential Health Implications of Fifth Generation (5G) Wireless Communication Technology: A Review of Emerging Biological and Epidemiological Concerns. *Saudi Journal of Medicine and Public Health*, *1*(1), 94–105. https://doi.org/10.64483/jmph-53
27. Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018). Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. *BMC psychiatry*, *18*(1), 1-14. https://doi.org/10.1186/s12888-018-1824-6
28. Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., ... & Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. *Nature medicine*, *27*(6), 1025-1033. https://doi.org/10.1038/s41591-021-01336-3
29. Mitchell, J. M., Ot'alora G, M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., ... & Yazar-Klosinski, B. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. *Nature Medicine*, *29*(10), 2473-2480. https://doi.org/10.1038/s41591-023-02565-4
30. Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., ... & Doblin, R. (2019). RETRACTED ARTICLE: MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. *Psychopharmacology*, *236*(9), 2735-2745. https://doi.org/10.1007/s00213-019-05249-5
31. Nasr, I. M., Al Ruweili, H. M. F., & alotaibi, H. moutlq M. (2025). The Significance of Routine Abdominal Ultrasound Before Bariatric Surgery. *Saudi Journal of Medicine and Public Health*, *2*(2), 147–158. https://doi.org/10.64483/jmph-68
32. Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018). Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. *Journal of psychopharmacology*, *32*(7), 756-769. https://doi.org/10.1177/0269881118780612
33. Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., ... & Araújo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. *Psychological medicine*, *49*(4), 655-663. doi:10.1017/S0033291718001356

34. Parley, K. A. Y. (1964). Supporting the patient. *AJN The American Journal of Nursing*, *64*(2), 80-82.
35. Penn, A. D., Phelps, J., Rosa, W. E., & Watson, J. (2024). Psychedelic-assisted psychotherapy practices and human caring science: Toward a care-informed model of treatment. *Journal of Humanistic Psychology*, *64*(4), 592-617. https://doi.org/10.1177/00221678211011013
36. Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., ... & Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. (2020). Psychedelics and psychedelic-assisted psychotherapy. *American Journal of Psychiatry*, *177*(5), 391-410. https://doi.org/10.1176/appi.ajp.2019.19010035
37. Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. *Frontiers in pharmacology*, *8*, 974. https://doi.org/10.3389/fphar.2017.00974
38. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., ... & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. *American Journal of Psychiatry*, *163*(11), 1905-1917. https://doi.org/10.1176/ajp.2006.163.11.1905
39. Saud Faleh Alanazi. (2024). Comparative Evaluation of the Pharmacological Mechanisms, Clinical Indications, and Risk Management Strategies of Epidural Anesthesia in Surgical and Obstetric Interventions. *Saudi Journal of Medicine and Public Health*, *1*(1), 47–57. https://doi.org/10.64483/jmph-36
40. Sessa, B. (2020). *The psychedelic renaissance: Reassessing the role of psychedelic drugs in 21st century psychiatry and society*. Aeon Books.
41. Spotswood, C. J. (2024). Psychedelics in psychiatry, the nursing influence, and the future of psychedelic therapies. *Journal of the American Psychiatric Nurses Association*, *30*(5), 906-913. https://doi.org/10.1177/10783903231222930
42. Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015). Psychotherapy for military-related PTSD: A review of randomized clinical trials. *Jama*, *314*(5), 489-500. doi:10.1001/jama.2015.8370
43. Strassman, R. (2000). *DMT: The spirit molecule: A doctor's revolutionary research into the biology of near-death and mystical experiences*. Simon and Schuster.
44. Utah Patients Coalition. (2023). *Psychedelic therapy access: Lessons from Oregon and Colorado*. https://www.utahpatients.org
45. Watson, J. (2013). Nursing: The philosophy and science of caring, revised edition. *Caring in nursing classics: An essential resource*, 243-264.
46. Weleff, J., Akiki, T. J., & Barnett, B. S. (2023). Bibliometric analysis of academic journal articles reporting results of psychedelic clinical studies. *Journal of Psychoactive Drugs*, *55*(4), 434-444. https://doi.org/10.1080/02791072.2022.2133757
47. Wheeler, S. W., & Dyer, N. L. (2020). A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future. *Psychology of Consciousness: Theory, Research, and Practice*, *7*(3), 279. https://psycnet.apa.org/doi/10.1037/cns0000237
48. WHO. (2022). *Mental health atlas 2022*. World Health Organization. https://www.who.int/publications/i/item/9789240036703
49. Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., ... & Gould, T. D. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature*, *533*(7604), 481-486. https://doi.org/10.1038/nature17998